Abstract: An offline mutual authentication method for battery swapping includes communicating a first authentication request to a battery by a computing device associated with a battery charger. A first authentication response is communicated to the computing device. The first authentication response is verified, and a first challenge request is communicated to the battery. A first challenge response is communicated to the computing device. The first challenge response is verified, and a battery authentication status is communicated to the battery. A second authentication request is communicated to the computing device. A second authentication response is communicated to the battery. The second authentication response is verified, and a second challenge request is communicated to the computing device. A second challenge response is communicated to the battery. The second challenge response is verified, and a charger authentication status is communicated by the battery to the computing device.

Abstract: An offline mutual authentication method for battery swapping includes communicating a first authentication request to a battery by a computing device associated with a battery charger. A first authentication response is communicated to the computing device. The first authentication response is verified, and a first challenge request is communicated to the battery. A first challenge response is communicated to the computing device. The first challenge response is verified, and a battery authentication status is communicated to the battery. A second authentication request is communicated to the computing device. A second authentication response is communicated to the battery. The second authentication response is verified, and a second challenge request is communicated to the computing device. A second challenge response is communicated to the battery. The second challenge response is verified, and a charger authentication status is communicated by the battery to the computing device.

Abstract: The present invention provides improved, commercially viable and consistently reproducible processes for the preparation of pure and stable crystalline Raltegravir potassium Form 3 and pharmaceutical composition thereof.

Abstract: The present invention provides process for preparation of dihydroxy benzoquinoline compound (III) comprising reacting dihydroxy isoquinoline compound (IV) or a salt thereof with (2-acetyl-4-methyl-pentyl)-trimethyl-ammonium iodide (V) and further converting it to tetrabenazine (I) and deutetrabenazine (II).

Abstract: The present invention provides improved, commercially viable and consistently reproducible processes for the preparation of pure and stable crystalline Raltegravir potassium Form 3 and pharmaceutical composition thereof.

Abstract: The present invention provides an improved process for preparation of an intermediate of apremilast. The present invention also provides an improved process for preparation of apremilast. This invention also provides novel polymorphs of apremilast. The present invention also provides pharmaceutical compositions of novel polymorphs of apremilast. This invention also provides a process for preparation of novel polymorphs of apremilast, which are cost-effective, robust, and viable at plant scale.

Abstract: A method of using NMR to estimate pore connectivity in a shale formation by estimating organic pore connectivity in a first sample of the shale formation and inorganic pore connectivity in a second sample of the shale formation based on uptake of brine and hydrocarbon phases. Porosity partitioning of the shale formation may be estimated with a third sample of the shale formation.

Abstract: A method of using NMR to estimate pore connectivity in a shale formation by estimating organic pore connectivity in a first sample of the shale formation and inorganic pore connectivity in a second sample of the shale formation based on uptake of brine and hydrocarbon phases. Porosity partitioning of the shale formation may be estimated with a third sample of the shale formation.

Abstract: Provided herein are novel salts of raltegravir, viz., meglumine salt, erbumine salt, ammonium salt, tris salt and L-arginine salt of raltegravir and processes for their preparation.

Abstract: The present invention provides novel salts of raltegravir, viz., meglumine salt, erbumine salt, ammonium salt, tris salt and L-arginine salt of raltegravir and processes for their preparation.

Abstract: The present invention is related to a novel process for the preparation of ulipristal (I) that comprises reaction of 17-?-ethynyl-17-?-hydroxy-11-?-(4-N,N-dimethylamino phenyl)- 9-norpregna-4,9-diene-3-one (III) with phenyl sulphenyl chloride (IVa) or p-nitro phenyl sulphenyl chloride (Nb) in the presence of organic base and solvent to give sulfoxide (Va) or (Vb) respectively. Sulfoxides (Va) or (Vb) are reacted with alkali metal alkoxide in alcoholic solvent followed by treatment with aqueous acid. The present invention also relates to novel intermediate 11-?-(4-N,N-dimethylaminophenyl)-21(p- nitro-phenyl-sulphinyl)-19-norpregna-4(5), 9(10), 17(20) 20-tetraene, 3-one (Vb).

Abstract: The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof.

Abstract: The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R)tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof.

Abstract: The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro-3-furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof.

Abstract: In order to realize some of the advantages described above, there is provided a computer system for verification of an intellectual property (IP) core in a system-on-chip (SoC). The system generates a plurality of verification specific abstracted views of the IP core, each of the plurality of verification specific abstracted views having a plurality of verification specific attributes at an input/output (I/O) interface of each of the abstracted view of the IP-core. A unified abstracted view of the IP-core is generated.

Abstract: The present invention provides novel salts of raltegravir, viz., meglumine salt, erbumine salt, ammonium salt, tris salt and L-arginine salt of raltegravir and processes for their preparation.

Abstract: In order to realize some of the advantages described above, there is provided a computer system for verification of an intellectual property (IP) core in a system-on-chip (SoC). The system generates a plurality of verification specific abstracted views of the IP core, each of the plurality of verification specific abstracted views having a plurality of verification specific attributes at an input/output (I/O) interface of each of the abstracted view of the IP-core. A unified abstracted view'of the IP-core is generated.

Abstract: The present invention relates to a crystalline oxybutynin base and process for preparing the same. Further, this invention discloses a process for preparing an acid addition salt of oxybutynin employing the crystalline oxybutynin base.

Abstract: The present invention relates to fosamprenavir calcium (Ia) substantially free of isomer impurity, (3R) tetrahydro -3 -furanyl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-(phosphonooxy)propyl carbamate (Ib), and its process for preparation thereof. The present invention also provides fosamprenavir calcium intermediate, (S)-3-tetrahydrofuranyl-N-succinimidyl carbonate (IIa) substantially free of (R)-3-tetrahydrofuranylsuccinimidyl carbonate (IIb) and its process for preparation thereof.

Abstract: The present invention is related to a novel process for the preparation of amisulpride (I) which involves: methylation of 4-amino-salicylic-acid (VI) with dimethyl sulphate and base, optionally in presence of TBAB to obtain 4-amino-2-methoxy methyl benzoate (VII) and (ii) oxidation of 4-amino-2-methoxy-5-ethyl thio benzoic acid (IX) or 4-amino-2-methoxy-5-ethyl thio methyl benzoate (X) with oxidizing agent in the presence of sodium tungstate or ammonium molybdate to give 2-methoxy-4-amino-5-ethyl-sulfonyl benzoic acid (IV) or 2-methoxy-4-amino-5-ethyl-sulfonyl methyl benzoate (XI) respectively.